NTRK1 and neoplasm: Since many of the CCLE drugs were receptor tyrosine kinase (RTK) inhibitors, we generated a heatmap showing significant GO enrichments corresponding to four major tumor associated RTK pathways – MAPK, RAS, PI3K, and JAK/STAT – as well as other GO terms associated with individual drugs (Fig. 4b).